Photo by nci from unsplash
e16802Background: PARP inhibitor (PARPi) has recently been approved for various cancers. However, trials have mostly recruited pts with germline BRCA (gBRCA) mutations, and it is unclear whether PA... Click to show full abstract
e16802Background: PARP inhibitor (PARPi) has recently been approved for various cancers. However, trials have mostly recruited pts with germline BRCA (gBRCA) mutations, and it is unclear whether PA...
Keywords:
germline brca;
rates survival;
similar response;
response rates;
survival parpi;
brca
Journal Title: Journal of Clinical Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!